ALLHAT says diuretics are better; ANBP2 says ACEs are better—can we resolve the differences?
Donald G. Vidt, MD
Consultant, Department of Nephrology and Hypertension, The Cleveland Clinic Foundation; member, Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; investigator, Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)
Address: Donald G. Vidt, MD, Department of Nephrology and Hypertension, A51, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195
ABSTRACTThe Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) and the second Australian National Blood Pressure Study (ANBP2) came to different conclusions about which class of drug to try first for treating high blood pressure: a diuretic or an angiotensin-converting enzyme (ACE) inhibitor. But when examined closely, the results may not be all that different after all.